These findings illustrate a novel mechanism for understanding OXA resistance in HCC, and suggest that UCA1/miR‐138‐5p/AKT/mTOR signaling axis has a potential therapeutic value for the treatment of OXA resistance in HCC patients. This evidence concerns the gene MTOR and hepatocellular carcinoma.